Korro Bio, Inc.
KRRO· Nasdaq
KRROKorro Bio, Inc.
Filed Mar 15, 2022 · 10-K · 74 days after period end · 0000950170-22-003655
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $0.00 | $9.95M | $4.71M | — |
| Net Income | -$21.50M | -$10.23M | -$5.49M | -$5.45M |
| EPS Diluted | — | -$0.30 | -$0.19 | -$3.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Mar 15, 2022 · 74 d after period end
